X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs BIOCON LTD - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA BIOCON LTD SANOFI INDIA/
BIOCON LTD
 
P/E (TTM) x 33.6 82.9 40.5% View Chart
P/BV x 6.4 7.8 81.9% View Chart
Dividend Yield % 1.4 0.2 887.8%  

Financials

 SANOFI INDIA   BIOCON LTD
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
BIOCON LTD
Mar-17
SANOFI INDIA/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs4,5601,162 392.5%   
Low Rs4,400483 911.9%   
Sales per share (Unadj.) Rs1,028.5194.6 528.6%  
Earnings per share (Unadj.) Rs129.034.4 374.8%  
Cash flow per share (Unadj.) Rs186.048.3 385.3%  
Dividends per share (Unadj.) Rs68.001.00 6,800.0%  
Dividend yield (eoy) %1.50.1 1,248.0%  
Book value per share (Unadj.) Rs753.6241.9 311.6%  
Shares outstanding (eoy) m23.03200.00 11.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.2 103.1%   
Avg P/E ratio x34.723.9 145.4%  
P/CF ratio (eoy) x24.117.0 141.4%  
Price / Book Value ratio x5.93.4 174.9%  
Dividend payout %52.72.9 1,814.1%   
Avg Mkt Cap Rs m103,174164,440 62.7%   
No. of employees `0003.69.2 39.2%   
Total wages/salary Rs m3,5927,470 48.1%   
Avg. sales/employee Rs Th6,537.74,213.9 155.1%   
Avg. wages/employee Rs Th991.4809.0 122.6%   
Avg. net profit/employee Rs Th819.8745.2 110.0%   
INCOME DATA
Net Sales Rs m23,68638,911 60.9%  
Other income Rs m7081,571 45.1%   
Total revenues Rs m24,39440,482 60.3%   
Gross profit Rs m5,2819,795 53.9%  
Depreciation Rs m1,3132,772 47.4%   
Interest Rs m15260 5.8%   
Profit before tax Rs m4,6618,334 55.9%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6911,616 104.6%   
Profit after tax Rs m2,9706,881 43.2%  
Gross profit margin %22.325.2 88.6%  
Effective tax rate %36.319.4 187.1%   
Net profit margin %12.517.7 70.9%  
BALANCE SHEET DATA
Current assets Rs m15,67340,477 38.7%   
Current liabilities Rs m6,67816,783 39.8%   
Net working cap to sales %38.060.9 62.4%  
Current ratio x2.32.4 97.3%  
Inventory Days Days7660 127.5%  
Debtors Days Days2283 26.9%  
Net fixed assets Rs m8,09845,073 18.0%   
Share capital Rs m2301,000 23.0%   
"Free" reserves Rs m17,08847,377 36.1%   
Net worth Rs m17,35648,377 35.9%   
Long term debt Rs m021,082 0.0%   
Total assets Rs m25,40093,942 27.0%  
Interest coverage x311.733.1 943.1%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x0.90.4 225.1%   
Return on assets %11.87.6 154.6%  
Return on equity %17.114.2 120.3%  
Return on capital %26.912.6 213.7%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,14512,988 55.0%   
Fx outflow Rs m6,8467,899 86.7%   
Net fx Rs m2995,089 5.9%   
CASH FLOW
From Operations Rs m3,2266,400 50.4%  
From Investments Rs m-1,555-4,985 31.2%  
From Financial Activity Rs m-1,818-1,775 102.4%  
Net Cashflow Rs m-147-473 31.1%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 60.4 20.6 293.2%  
Indian inst/Mut Fund % 14.4 8.4 171.4%  
FIIs % 14.6 10.7 136.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 19.9 52.8%  
Shareholders   15,184 109,995 13.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   ABBOTT INDIA  JUBILANT LIFE SCIENCES  DIVIS LABORATORIES  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  

Compare SANOFI INDIA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 23, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS